{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiff3fnlkh6js47winhpouwwhkhyyahc26lmjb2rn7hugr2hjdr4ai",
    "uri": "at://did:plc:nnaxwirbqywidimahadp42bj/app.bsky.feed.post/3mlnnwomxyq72"
  },
  "path": "/alkermes-announces-positive-topline-results-from-revitalyz%e2%84%a0-phase-3-study-evaluating-lumryz-sodium-oxybate-extended-release-in-adults-with-idiopathic-hypersomnia/",
  "publishedAt": "2026-05-12T11:06:59.000Z",
  "site": "https://www.cityam.com",
  "tags": [
    "Product/Service"
  ],
  "textContent": "– LUMRYZ Met All Primary and Key Secondary Endpoints Demonstrating Statistically Significant and Clinically Meaningful Improvements Compared to Placebo in Excessive Daytime Sleepiness and Patient-Reported Disease Severity – – Safety Profile Consistent With Known Safety Profile of LUMRYZ –",
  "title": "Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia"
}